SELLAS Life Sciences Group, Inc. (SLS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-18

SELLAS Life Sciences Group, Inc. (SLS) has filed 1 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-18. 4 Form 8-K material event filings were reported by SLS in the last 90 days. InsiderAlpha tracks every SLS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About SELLAS Life Sciences Group, Inc. (SLS)

SEC CIK	0001390478

90-Day SEC Filing Activity

Form 4 filings (90d)	1
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-06-18

Recent SLS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-16	Stergiou Angelos M.	President and CEO	A — Grant or award	1.06M	$0.00	—	SEC
2025-12-03	Burns John Thomas	CFO	J — Other acquisition / disposition	58.6K	$1.50	$88K	SEC
2025-12-03	Stergiou Angelos M.	President and CEO	J — Other acquisition / disposition	187.1K	$1.50	$281K	SEC
2025-12-03	CICIC DRAGAN	SVP, Chief Development Officer	J — Other acquisition / disposition	63.8K	$1.50	$96K	SEC
2025-06-12	VAN NOSTRAND ROBERT L	Director	P — Open-market purchase	10.0K	$1.48	$15K	SEC
2024-12-04	Stergiou Angelos M.	President and CEO	J — Other acquisition / disposition	28.3K	$1.13	$32K	SEC
2024-12-04	CICIC DRAGAN	SVP, Chief Development Officer	J — Other acquisition / disposition	8.3K	$1.13	$9K	SEC
2024-12-04	Burns John Thomas	CFO	J — Other acquisition / disposition	7.2K	$1.13	$8K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for SELLAS Life Sciences Group, Inc. (SLS). Updated in real time as new filings are submitted to the SEC.

Most-Active SLS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Stergiou Angelos M.	1	—

Recent SLS Form 8-K Material Events

2026-06-25 — Item 5.02, 9.01 [SEC]
2026-06-18 — Item 5.07 [SEC]
2026-06-02 — Item 8.01, 9.01 [SEC]
2026-05-12 — Item 2.02, 9.01 [SEC]
2026-03-19 — Item 2.02, 9.01 · Earnings · neutral [SEC]
SELLAS Life Sciences announced its financial results for the year ended December 31, 2025 and provided a corporate update on March 19, 2026. The filing contains standard annual financial results disclosure without explicit beat/miss or guidance language.

Recent Insider Filings

2026-06-18 — Stergiou Angelos M. (President and CEO)
2025-12-05 — Burns John Thomas (CFO)
2025-12-05 — Stergiou Angelos M. (President and CEO)
2025-12-05 — CICIC DRAGAN (SVP, Chief Development Officer)
2025-11-21 — Kalin Katherine Bach (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SLS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

SLS Insider Trading — FAQ

What is the latest insider trade for SLS?: SELLAS Life Sciences Group, Inc. (SLS) had 1 insider filings in the last 90 days, with the most recent on 2026-06-18. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying SLS stock?: 0 insider purchases of SLS were filed in the last 90 days.
How many insiders are selling SLS stock?: 0 insider sales of SLS were filed in the last 90 days.
Where can I see SLS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every SLS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live SLS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.